False-positive positron emission tomography appearance with18F-fluorodeoxyglucose after definitive radiotherapy for cancer of the mobile tongue

2009 ◽  
Vol 82 (973) ◽  
pp. e3-e7 ◽  
Author(s):  
Y ARIJI ◽  
N FUWA ◽  
T KODAIRA ◽  
H TACHIBANA ◽  
T NAKAMURA ◽  
...  
2008 ◽  
Vol 122 (12) ◽  
pp. 1394-1396 ◽  
Author(s):  
E J Damrose

AbstractObjectives:To describe the positron emission tomography and computed tomography features of injected calcium hydroxylapatite, and to discuss how these may be mistaken for malignancy.Case report:Positron emission tomography is now readily employed in the staging and monitoring of patients with head and neck carcinoma. Concomitant with the growing use of this modality has been the increasing popularity of injected calcium hydroxylapatite to treat glottic incompetence secondary to vocal fold paralysis or following partial laryngectomy. A patient developed aspiration following near-total laryngectomy and subsequently underwent injection of calcium hydroxylapatite, with effective resolution of the aspiration. The patient underwent positron emission tomography scanning as part of routine tumour surveillance; this showed intense tracer uptake at the site of injection, and this pattern persisted for one year following injection.Conclusions:As injectable calcium hydroxylapatite becomes more widely used, especially in the treatment of patients with a history of head and neck cancer, physicians should be aware it may cause a potentially misleading, false positive positron emission tomography finding.


2020 ◽  
Vol 6 (4) ◽  
pp. 00103-2020
Author(s):  
J. Michael Ramsahai ◽  
Christine Molnar ◽  
Lawrence Lou ◽  
Winston Ying ◽  
Paul MacEachern ◽  
...  

BackgroundProper staging of the mediastinum is an essential component of lung cancer evaluation. Positron emission tomography–computed tomography (PETCT) and endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) are an integral part of this process. False-positive PETCT results can occur following surgical procedures but has not been demonstrated following EBUS-TBNA. We aimed to determine whether false-positive PETCT rates increase when EBUS-TBNA is performed prior to PETCT.Study design and methodsA retrospective review was carried out of clinical cases that underwent both PETCT and EBUS-TBNA within 30 days for the suspected malignancy. The impact of test sequence on the PETCT false-positive rate (FPR) was determined using Generalised Estimating Equation logistic regression analysis.ResultsA total of 675 lymph node stations were sampled and imaged on PETCT. Overall, 332 (49.2%) nodes were sampled by EBUS-TBNA before PETCT, and 343 (50.8%) afterwards, with the interval between EBUS and subsequent PETCT being a mean±sd of 11.6±6.8 days (range 1–29). The FPR on qualitative PETCT for the EBUS first group was 41 (23.2%) out of 164, and for PETCT first it was 57 (29.0%) out of 193 for a difference of 5.8% (95% CI −3.4–14.7, p=0.22). In the regression model, EBUS as the first test was associated with a lower FPR when using the clinical PETCT interpretation.InterpretationThe performance of EBUS-TBNA sampling did not influence the FPR of PETCT when bronchoscopy took place in the 30 days prior to testing. Test sequence should be selected based on other clinical considerations.


Sign in / Sign up

Export Citation Format

Share Document